These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18260176)

  • 21. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.
    Doran MF; Crowson CS; Pond GR; O'Fallon WM; Gabriel SE
    Arthritis Rheum; 2002 Sep; 46(9):2287-93. PubMed ID: 12355475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis.
    Van Doornum S; Brand C; King B; Sundararajan V
    Arthritis Rheum; 2006 Jul; 54(7):2061-8. PubMed ID: 16802340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.
    Bernatsky S; Clarke AE; Suissa S
    Arch Intern Med; 2008 Feb; 168(4):378-81. PubMed ID: 18299492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.
    Sihvonen S; Korpela M; Mustonen J; Huhtala H; Karstila K; Pasternack A
    J Rheumatol; 2006 Sep; 33(9):1740-6. PubMed ID: 16881099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
    Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
    Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    Arthritis Rheum; 2007 Dec; 57(8):1431-8. PubMed ID: 18050184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
    Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
    Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
    J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
    Nicola PJ; Maradit-Kremers H; Roger VL; Jacobsen SJ; Crowson CS; Ballman KV; Gabriel SE
    Arthritis Rheum; 2005 Feb; 52(2):412-20. PubMed ID: 15692992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lung cancer after exposure to disease modifying anti-rheumatic drugs.
    Bernatsky S; Clarke A; Suissa S
    Lung Cancer; 2008 Feb; 59(2):266-9. PubMed ID: 17673329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry.
    Marra CA; Esdaile JM; Guh D; Fisher JH; Chalmers A; Anis AH
    Arthritis Rheum; 2001 Jun; 45(3):240-5. PubMed ID: 11409664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
    Zintzaras E; Voulgarelis M; Moutsopoulos HM
    Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.